Aspiriant LLC
PRVB

Aspiriant LLC’s Provention Bio, Inc. Common Stock PRVB Stock Holding History

Aspiriant LLC’s Portfolio PRVB Stock Details PRVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-11,000
Closed -$44K – 282
2022
Q2 		$44K Buy
+11,000
New +$52.1K ﹤0.01% 271

Other funds holding PRVB

Sessa Capital
Sessa Capital New York $5.98B AUM 99.85% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Aspiriant LLC's PRVB Position: Q3 2022 in Review

Aspiriant LLC sold out of Provention Bio, Inc. Common Stock (PRVB) in Q3 2022, closing a stake of 11,000 shares — an estimated $44K sold.

Aspiriant LLC first reported a position in PRVB in Q2 2022 and held it in 1 quarter. The position peaked at $44K in Q2 2022. 112 funds tracked by Wall St. Rank hold PRVB as of Q3 2022.

  • Aspiriant LLC reported no remaining Provention Bio, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Aspiriant LLC sold 11,000 Provention Bio, Inc. Common Stock shares in Q3 2022, an estimated $44K.
  • Aspiriant LLC first reported a position in Provention Bio, Inc. Common Stock in Q2 2022 and held it in 1 quarter.
  • Aspiriant LLC's Provention Bio, Inc. Common Stock position peaked at $44K in Q2 2022.
  • 112 funds tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q3 2022.

Based on Aspiriant LLC's 13F filing for Q3 2022, filed 28 Oct 2022.